Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Osteosarcopenia linked to much higher risk of death after TAVR—CT screening may prove valuable

Osteosarcopenia, an age-related condition associated with deterioration in the muscles and bones, nearly triples a patient’s risk of dying within one year of undergoing TAVR. 

alternative approaches for transcatheter aortic valve replacement procedures

Transcaval TAVR a safe, effective alternative for patients with severe AS

Researchers examined data from eight different studies, noting that transcaval TAVR appears to be a "viable alternative" when transfemoral access is not an option. The procedure was linked to an overall success rate of 98.5%.

Transcatheter mitral valve interventions linked to lower stroke risk than surgery

Researchers performed a new meta-analysis of data from more than 51,000 patients. They examined a wide range of outcomes that also included AFib and all-cause mortality.

Newsweek ranked the 50 best heart hospitals in the world

New York Valves, CRF’s newest cardiology conference, makes heart team collaborations a priority

New York Valves: The Structural Heart Summit replaces the Transcatheter Valve Therapy conference CRF hosted for many years. The three-day event will include 12 late-breaking clinical trials focused on TAVR and new treatments for the mitral and tricuspid valves. 

doctor examines patient data on their tablet

AVR for moderate AS: New 10-year data highlight clear benefits of TAVR, surgery

New research out of Cleveland Clinic explored long-term outcomes among patients with moderate aortic stenosis who were treated with TAVR, SAVR or clinical surveillance. TAVR and SAVR were both associated with clear improvements compared to surveillance alone. 

The EuroPCR 2024 meeting May 14-17 in Paris included four days of late-breaking interventional cardiology science presentations featured 12,100 participants, more than 550 educational sessions and 12 live cases. Photo courtesy of EuroPCR

5 takeaways from late-breaking studies at EuroPCR

The Society for Cardiovascular Angiography and Interventions offers its top five key takeaways from the EuroPCR 2024 meeting last week.

Medicare money payment physician

Hospital to pay $24.3M over TAVR allegations

According to a whistleblower, Cape Cod Hospital performed hundreds of TAVR procedures without following specific government requirements.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve noninferior to similar devices from Medtronic, Edwards after 30 days

The balloon-expandable valve is already approved for use in India and Europe. New data presented at EuroPCR 2024 in Paris compared it to contemporary devices seen by many as the gold standard for TAVR care. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup